Orphan drug exclusivity provides seven years of market protection for rare disease drugs in the U.S. Enacted in 1983, it drives development for conditions affecting fewer than 200,000 people. Since then, over 500 drugs have been approved, up from 38 in the prior decade. Challenges include pricing and global variations in exclusivity periods.